Key Takeaways
- • IFF has agreed to sell its Food Ingredients business to funds advised by CVC Capital Partners in a transaction valuing the unit at approximately $4.3 billion, or about 10x enterprise value-to-EBITDA.
- • IFF will retain a roughly 10% minority equity stake in the business, valued at approximately $200 million, allowing it to participate in future value creation under CVC ownership.
- • The divestiture is a central step in IFF's portfolio optimization, concentrating resources on its Taste, Scent, and Health & Biosciences segments, which management describes as higher-growth and higher-margin.
- • Management expects the sale to produce a more focused company with improved cash flow characteristics and greater financial flexibility.
Summary
IFF (NYSE: IFF), a global flavors, fragrances, food ingredients, and health and biosciences company, announced on May 29, 2026 that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a global private markets manager. The transaction values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x.
As part of the deal, IFF will retain an approximately 10% minority equity interest in Food Ingredients, worth roughly $200 million. IFF said the retained stake permits continued collaboration between the two companies and allows IFF and its shareholders to share in future value creation under the new ownership structure.
The company framed the transaction as a significant milestone in its ongoing portfolio optimization initiative. IFF expects the sale to strengthen its focus on Taste, Scent, and Health & Biosciences, which it characterized as its innovation-driven businesses. Following the divestiture, IFF expects to have improved cash flow characteristics, greater financial flexibility, and a stronger position to meet its growth and profitability objectives.
Erik Fyrwald, IFF's chief executive, said the transaction allows the company to concentrate resources on higher-growth, higher-margin segments. He said the simplified portfolio would accelerate innovation, increase investment in research and development, and further integrate the company's biotechnology and naturals capabilities across its global platform. He added that the retained minority stake would let IFF participate in the upside of a strong business under dedicated ownership.
Coverage from trade and financial outlets, including reports that CVC is buying the unit in a $4.3 billion deal, is consistent with the company's terms. CVC's own announcement described the business as joining its U.S. portfolio, citing its global reach and proprietary technical capabilities.
As part of the deal, IFF will retain an approximately 10% minority equity interest in Food Ingredients, worth roughly $200 million. IFF said the retained stake permits continued collaboration between the two companies and allows IFF and its shareholders to share in future value creation under the new ownership structure.
The company framed the transaction as a significant milestone in its ongoing portfolio optimization initiative. IFF expects the sale to strengthen its focus on Taste, Scent, and Health & Biosciences, which it characterized as its innovation-driven businesses. Following the divestiture, IFF expects to have improved cash flow characteristics, greater financial flexibility, and a stronger position to meet its growth and profitability objectives.
Erik Fyrwald, IFF's chief executive, said the transaction allows the company to concentrate resources on higher-growth, higher-margin segments. He said the simplified portfolio would accelerate innovation, increase investment in research and development, and further integrate the company's biotechnology and naturals capabilities across its global platform. He added that the retained minority stake would let IFF participate in the upside of a strong business under dedicated ownership.
Coverage from trade and financial outlets, including reports that CVC is buying the unit in a $4.3 billion deal, is consistent with the company's terms. CVC's own announcement described the business as joining its U.S. portfolio, citing its global reach and proprietary technical capabilities.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.